Altered expression of brain acetylcholinesterase in FTDP-17 human tau transgenic mice

Neurobiology of Aging

Volumn 33, Issue 3, 2012, Pages 624.e23-624.e34

  Silveyra, María Ximena ^a,b   García Ayllón, María Salud ^a,b   de Barreda, Elena Gómez ^b,c   Small, David H ^d   Martínez, Salvador ^a   Avila, Jesús ^b,c   Sáez Valero, Javier ^a,b  

^a MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^d UNIVERSITY OF TASMANIA   (Australia)

Author keywords

Acetylcholinesterase; Alzheimer's disease; Cholinergic; Tau; Tauopathy; Transgenic

Indexed keywords

ACETYLCHOLINE; ACETYLCHOLINESTERASE; CHOLINE ACETYLTRANSFERASE; MUTANT PROTEIN; TAU PROTEIN; TETRAMER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CELL LINE; CELL STRAIN SH SY5Y; CHEMICAL STRUCTURE; CONTROLLED STUDY; ENZYME ACTIVITY; HYDROLYSIS; MALE; MISSENSE MUTATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; TAUOPATHY; TRANSGENIC MOUSE;

EID: 84855819161     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2011.03.006     Document Type: Article

References (68)

1. Alonso A.del C., Mederlyova A., Novak M., Grundke-Iqbal I., Iqbal K. Promotion of hyperphosphorylation by frontotemporal dementia tau mutations. J. Biol. Chem 2004, 279:34873-34881.
2. Beeri R., Andres C., Lev-Lehman E., Timberg R., Huberman T., Shani M., Soreq H. Transgenic expression of human acetylcholinesterase induces progressive cognitive deterioration in mice. Curr. Biol 1995, 5:1063-1071.
3. Boon W.C., van den Buuse M., Wegener N., Martin S., Chua H.K., Bush A.I., Masters C.L., Adlard P.A., Li Q.X. Behavioural phenotype of APPC100V717F transgenic mice over-expressing a mutant Abeta-bearing fragment is associated with reduced NMDA receptor density. Behav. Brain Res 2010, 209:27-35.
4. Brunden K.R., Trojanowski J.Q., Lee V.M. Evidence that non-fibrillar tau causes pathology linked to neurodegeneration and behavioral impairments. J. Alzheimers Dis 2008, 14:393-399.
5. Chacón M.A., Reyes A.E., Inestrosa N.C. Acetylcholinesterase induces neuronal cell loss, astrocyte hypertrophy and behavioral deficits in mammalian hippocampus. J. Neurochem 2003, 87:195-204.
6. Chatel J.M., Grassi J., Frobert Y., Massoulié J., Vallette F.M. Existence of an inactive pool of acetylcholinesterase in chicken brain. Proc. Natl. Acad. Sci. 1993, 90:2476-2480.
7. Davies P., Maloney A.J. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976, 2:1403.
8. De Sarno P., Bijur G.N., Zmijewska A.A., Li X., Jope R.S. In vivo regulation of GSK3 phosphorylation by cholinergic and NMDA receptors. Neurobiol. Aging 2006, 27:413-422.
9. Dobbertin A., Hrabovska A., Dembele K., Camp S., Taylor P., Krejci E., Bernard V. Targeting of acetylcholinesterase in neurons in vivo: a dual processing function for the proline-rich membrane anchor subunit and the attachment domain on the catalytic subunit. J. Neurosci 2009, 29:4519-4530.
10. Dumont M., Lalonde R., Ghersi-Egea J.F., Fukuchi K., Strazielle C. Regional acetylcholinesterase activity and its correlation with behavioral performances in 15-month old transgenic mice expressing the human C99 fragment of APP. J. Neural Transm 2006, 113:1225-1241.
11. Doody R.S., Ferris S.H., Salloway S., Sun Y., Goldman R., Watkins W.E., Xu Y., Murthy A.K. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial. Neurology 2009, 72:1555-1561.
12. Engel T., Lucas J.J., Gómez-Ramos P., Moran M.A., Avila J., Hernández F. Cooexpression of FTDP-17 tau and GSK-3beta in transgenic mice induce tau polymerization and neurodegeneration. Neurobiol. Aging 2006, 27:1258-1268.
13. Fishman E.B., Siek G.C., MacCallum R.D., Bird E.D., Volicer L., Marquis J.K. Distribution of the molecular forms of acetylcholinesterase in human brain: alterations in dementia of the Alzheimer type. Ann. Neurol 1986, 19:246-252.
14. Fodero L.R., Sáez-Valero J., McLean C.A., Martins R.N., Beyreuther K., Masters C.L., Robertson T.A., Small D.H. Altered glycosylation of acetylcholinesterase in APP (SW) Tg2576 transgenic mice occurs prior to amyloid plaque deposition. J. Neurochem 2002, 81:441-448.
15. Fodero L.R., Mok S.S., Losic D., Martin L.L., Aguilar M.I., Barrow C.J., Livett B.G., Small D.H. Alpha7-nicotinic acetylcholine receptors mediate an Abeta(1-42)-induced increase in the level of acetylcholinesterase in primary cortical neurones. J. Neurochem 2004, 88:1186-1193.
16. Forlenza O.V., Spink J.M., Dayanandan R., Anderton B.H., Olesen O.F., Lovestone S. Muscarinic agonists reduce tau phosphorylation in non-neuronal cells via GSK-3beta inhibition and in neurons. J. Neural Transm 2000, 107:1201-1212.
17. García-Ayllón M.S., Silveyra M.X., Candela A., Compañ A., Clària J., Jover R., Pérez-Mateo M., Felipo V., Martínez S., Galcerán J., Sáez-Valero J. Changes in liver and plasma acetylcholinesterase in rats with cirrhosis induced by bile duct ligation. Hepatology 2006, 43:444-453.
18. García-Ayllón M.S., Cauli O., Silveyra M.X., Rodrigo R., Candela A., Compañ A., Jover R., Pérez-Mateo M., Martínez S., Felipo V., Sáez-Valero J. Brain cholinergic impairment in liver failure. Brain 2008, 131:2946-2956.
19. García-Ayllón M.S., Riba-Llena I., Serra-Basante C., Alom J., Boopathy R., Sáez-Valero J. Altered levels of acetylcholinesterase in Alzheimer plasma. PLoS One 2010, 5:e8701.
20. Goedert M., Crowther R.A., Spillantini M.G. Tau mutations cause frontotemporal dementias. Neuron 1998, 21:955-958.
21. Gómez-Ramos A., Díaz-Hernández M., Rubio A., Miras-Portugal M.T., Avila J. Extracellular tau promotes intracellular calcium increase through M1 and M3 muscarinic receptors in neuronal cells. Mol. Cell. Neurosci 2008, 37:673-681.
22. Götz J., Chen F., Barmettler R., Nitsch R.M. Tau filament formation in transgenic mice expressing P301L tau. J. Biol. Chem 2001, 276:529-534.
23. Grisaru D., Sternfeld M., Eldor A., Glick D., Soreq H. Structural roles of acetylcholinesterase variants in biology and pathology. Eur. J. Biochem 1999, 264:672-686.
24. Hellström-Lindahl E., Moore H., Nordberg A. Increased levels of tau protein in SH-SY5Y cells after treatment with cholinesterase inhibitors and nicotinic agonists. J. Neurochem 2000, 74:777-784.
25. Herholz K., Weisenbach S., Zündorf G., Lenz O., Schröder H., Bauer B., Kalbe E., Heiss W.D. In vivo study of acetylcholine esterase in basal forebrain, amygdala, and cortex in mild to moderate Alzheimer disease. Neuroimage 2004, 21:136-143.
26. Hernández F., Avila J. Tauopathies. Cell. Mol. Life Sci 2007, 64:2219-2233.
27. Hernández F., Gómez de Barreda E., Fuster-Matanzo A., Lucas J.J., Avila J. GSK3: a possible link between beta amyloid peptide and tau protein. Exp. Neurol 2010, 223:322-325.
28. Hirano S., Shinotoh H., Kobayashi T., Tsuboi Y., Wszolek Z.K., Aotsuka A., Tanaka N., Ota T., Fukushi K., Tanada S., Irie T. Brain acetylcholinesterase activity in FTDP-17 studied by PET. Neurology 2006, 66:1276-1277.
29. Hu W., Gray N.W., Brimijoin S. Amyloid-beta increases acetylcholinesterase expression in neuroblastoma cells by reducing enzyme degradation. J. Neurochem 2003, 86:470-478.
30. Hutton M., Lendon C.L., Rizzu P., Baker M., Froelich S., Houlden H., Pickering-Brown S., Chakraverty S., Isaacs A., Grover A., Hackett J., Adamson J., Lincoln S., Dickson D., Davies P., Petersen R.C., Stevens M., de Graaff E., Wauters E., van Baren J., Hillebrand M., Joosse M., Kwon J.M., Nowotny P., Che L.K., Norton J., Morris J.C., Reed L.A., Trojanowski J., Basun H., Lannfelt L., Neystat M., Fahn S., Dark F., Tannenberg T., Dodd P.R., Hayward N., Kwok J.B., Schofield P.R., Andreadis A., Snowden J., Craufurd D., Neary D., Owen F., Oostra B.A., Hardy J., Goate A., van Swieten J., Mann D., Lynch T., Heutink P. Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998, 393:702-705.
31. Inestrosa N.C., Alvarez A., Pérez C.A., Moreno R.D., Vicente M., Linker C., Casanueva O.I., Soto C., Garrido J. Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron 1996, 16:881-891.
32. Iyo M., Namba H., Fukushi K., Shinotoh H., Nagatsuka S., Suhara T., Sudo Y., Suzuki K., Irie T. Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer's disease. Lancet 1997, 349:1805-1809.
33. Karnovsky M.J., Roots L. A direct-coloring thiocholine method for cholinesterases. J. Histochem. Cytochem 1964, 12:219-221.
34. Kaufer D., Friedman A., Seidman S., Soreq H. Acute stress facilitates long-lasting changes in cholinergic gene expression. Nature 1998, 393:373-377.
35. Köhler C., Bista P., Götz J., Schröder H. Analysis of the cholinergic pathology in the P301L tau transgenic pR5 model of tauopathy. Brain Res 2010, 1347:111-124.
36. Lewis J., McGowan E., Rockwood J., Melrose H., Nacharaju P., Van Slegtenhorst M., Gwinn-Hardy K., Paul Murphy M., Baker M., Yu X., Duff K., Hardy J., Corral A., Lin W.L., Yen S.H., Dickson D.W., Davies P., Hutton M. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat. Genet 2000, 25:402-405.
37. Li Q.X., Maynard C., Cappai R., McLean C.A., Cherny R.A., Lynch T., Culvenor J.G., Trevaskis J., Tanner J.E., Bailey K.A., Czech C., Bush A.I., Beyreuther K., Masters C.L. Intracellular accumulation of detergent-soluble amyloidogenic A beta fragment of Alzheimer's disease precursor protein in the hippocampus of aged transgenic mice. J. Neurochem 1999, 72:2479-2487.
38. Lim F., Hernández F., Lucas J.J., Gómez-Ramos P., Morán M.A., Avila J. FTDP-17 mutations in tau transgenic mice provoke lysosomal abnormalities and Tau filaments in forebrain. Mol. Cell. Neurosci 2001, 18:702-714.
39. Luo Z., Fuentes M.E., Taylor P. Regulation of acetylcholinesterase mRNA stability by calcium during differentiation from myoblasts to myotubes. J. Biol. Chem 1994, 269:27216-27223.
40. Martínez A., Lahiri D.K., Giacobini E., Greig N.H. Advances in Alzheimer therapy: understanding pharmacological approaches to the disease. Curr. Alzheimer Res 2009, 6:83-85.
41. Massoulié J. The origin of the molecular diversity and functional anchoring of cholinesterases. Neurosignals 2002, 11:130-143.
42. Masters C.L., Simms G., Weinman N.A., Multhaup G., McDonald B.L., Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. U. S. A 1985, 82:4245-4249.
43. Melo J.B., Agostinho P., Oliveira C.R. Involvement of oxidative stress in the enhancement of acetylcholinesterase activity induced by amyloid beta-peptide. Neurosci. Res 2003, 45:117-127.
44. Mesulam M.M., Morán M.A. Cholinesterases within neurofibrillary tangles related to age and Alzheimer's disease. Ann. Neurol 1987, 22:223-228.
45. Montejo de Garcini E., de la Luna S., Dominguez J.E., Avila J. Overexpression of tau protein in COS-1 cells results in the stabilization of centrosome-independent microtubules and extension of cytoplasmic processes. Mol. Cell. Biochem 1994, 130:187-196.
46. Morris J.C. Challenging assumptions about Alzheimer's disease: mild cognitive impairment and the cholinergic hypothesis. Ann. Neurol 2002, 51:143-144.
47. Navarro P., Guerrero R., Gallego E., Avila J., Luquin R., Ruiz P.J., Sanchez M.P. Memory and exploratory impairment in mice that lack the Park-2 gene and that over-express the human FTDP-17 mutant Tau. Behav. Brain Res 2008, 189:350-356.
48. Noh M.Y., Koh S.H., Kim Y., Kim H.Y., Cho G.W., Kim S.H. Neuroprotective effects of donepezil through inhibition of GSK-3 activity in amyloid-beta-induced neuronal cell death. J. Neurochem 2009, 108:1116-1125.
49. Pérez M., Hernández F., Lim F., Díaz-Nido J., Avila J. Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model. J. Alzheimers Dis 2003, 5:301-308.
50. Perrier N.A., Salani M., Falasca C., Bom S., Augusti-Tocco G., Massoulié J. The readthrough variant of acetylcholinesterase remains very minor after heat shock, organophosphate inhibition and stress, in cell culture and in vivo. J. Neurochem 2005, 94:629-638.
51. Perry E.K., Perry R.H., Blessed G., Tomlinson B.E. Necropsy evidence of central cholinergic deficits in senile dementia. Lancet 1977, 1:189.
52. Poorkaj P., Bird T.D., Wijsman E., Nemens E., Garruto R.M., Anderson L., Andreadis A., Wiederholt W.C., Raskind M., Schellenberg G.D. Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann. Neurol 1998, 43:815-825.
53. Raschetti R., Albanese E., Vanacore N., Maggini M. Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials. PLoS Med 2007, 4:e338.
54. Rees T., Hammond P.I., Soreq H., Younkin S., Brimijoin S. Acetylcholinesterase promotes beta-amyloid plaques in cerebral cortex. Neurobiol. Aging 2003, 24:777-787.
55. Rotundo R.L. Biogenesis of acetylcholinesterase molecular forms in muscle. Evidence for a rapidly turning over, catalytically inactive precursor pool. J. Biol. Chem 1988, 263:19398-19406.
56. Sadot E., Gurwitz D., Barg J., Behar L., Ginzburg I., Fisher A. Activation of m1 muscarinic acetylcholine receptor regulates tau phosphorylation in transfected PC12 cells. J. Neurochem 1996, 66:877-880.
57. Sáez-Valero J., Tornel P.L., Muñoz-Delgado E., Vidal C.J. Amphiphilic and hydrophilic forms of acetyl- and butyrylcholinesterase in human brain. J. Neurosci. Res 1993, 35:678-689.
58. Sáez-Valero J., Sberna G., McLean C.A., Small D.H. Molecular isoform distribution and glycosylation of acetylcholinesterase are altered in brain and cerebrospinal fluid of patients with Alzheimer's disease. J. Neurochem 1999, 72:1600-1608.
59. Sáez-Valero J., de Ceballos M.L., Small D.H., de Felipe C. Changes in molecular isoform distribution of acetylcholinesterase in rat cortex and cerebrospinal fluid after intracerebroventricular administration of amyloid beta-peptide. Neurosci. Lett 2002, 325:199-202.
60. SantaCruz K., Lewis J., Spires T., Paulson J., Kotilinek L., Ingelsson M., Guimaraes A., DeTure M., Ramsden M., McGowan E., Forster C., Yue M., Orne J., Janus C., Mariash A., Kuskowski M., Hyman B., Hutton M., Ashe K.H. Tau suppression in a neurodegenerative mouse model improves memory function. Science 2005, 309:476-481.
61. Sberna G., Sáez-Valero J., Beyreuther K., Masters C.L., Small D.H. The amyloid b-protein of Alzheimer's disease increases acetylcholinesterase expression by increasing intracellular calcium in embryonal carcinoma P19 cells. J. Neurochem 1997, 69:1177-1184.
62. Sberna G., Sáez-Valero J., Li Q.X., Czech C., Beyreuther K., Masters C.L., McLean C.A., Small D.H. Acetylcholinesterase is increased in the brains of transgenic mice expressing the C-terminal fragment (CT100) of the beta-amyloid protein precursor of Alzheimer's disease. J. Neurochem 1998, 71:723-731.
63. Shinotoh H., Namba H., Fukushi K., Nagatsuka S., Tanaka N., Aotsuka A., Ota T., Tanada S., Irie T. Progressive loss of cortical acetylcholinesterase activity in association with cognitive decline in Alzheimer's disease: a positron emission tomography study. Ann. Neurol 2000, 48:194-200.
64. Small D.H., Maksel D., Kerr M.L., Ng J., Hou X., Chu C., Mehrani H., Unabia S., Azari M.F., Loiacono R., Aguilar M.I., Chebib M. The beta-amyloid protein of Alzheimer's disease binds to membrane lipids but does not bind to the alpha7 nicotinic acetylcholine receptor. J. Neurochem 2007, 101:1527-1538.
65. Small D.H., Michaelson S., Sberna G. Non-classical actions of cholinesterases: role in cellular differentiation, tumorigenesis and Alzheimer's disease. Neurochem. Int 1996, 28:453-483.
66. Spillantini M.G., Murrell J.R., Goedert M., Farlow M.R., Klug A., Ghetti B. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc. Natl. Acad. Sci. U. S. A 1998, 95:7737-7741.
67. Sternfeld M., Shoham S., Klein O., Flores-Flores C., Evron T., Idelson G.H., Kitsberg D., Patrick J.W., Soreq H. Excess read-through acetylcholinesterase attenuates but the synaptic variant intensifies neurodeterioration correlates. Proc. Natl. Acad. Sci. U. S. A 2000, 97:8647-8652.
68. Ulrich J., Meier-Ruge W., Probst A., Meier E., Ipsen S. Senile plaques: staining for acetylcholinesterase and A4 protein: a comparative study in the hippocampus and entorhinal cortex. Acta Neuropathol 1990, 80:624-628.